Portola Files Registration Statement for Proposed Initial Public Offering

Portola Files Registration Statement for Proposed Initial Public Offering 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/12/13 --   Portola
Pharmaceuticals, Inc. announced today that it has filed a
registration statement on Form S-1 with the U.S. Securities and
Exchange Commission relating to a proposed initial public offering of
its common stock. The number of shares to be offered and the price
range for the offering have not yet been determined. 
Morgan Stanley and Credit Suisse are acting as the joint book-running
managers for the offering. Cowen and Company and William Blair are
acting as co-managers. This offering will be made only by means of a
prospectus. A copy of the preliminary prospectus, when available, may
be obtained from the offices of Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, New
York 10014, or by email at prospectus@morganstanley.com or Credit
Suisse Securities (USA) LLC, Attention: Prospectus Department, One
Madison Avenue, New York, NY 10010, by email at
newyork.prospectus@credit-suisse.com or by toll-free call to (800)
221-1037.  
Although a registration statement relating to these securities has
been filed with the U.S. Securities and Exchange Commission, it has
not yet become effective. These securities may not be sold nor may
offers to buy be accepted prior to the time the registration
statement becomes effective.  
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.  
About Portola Pharmaceuticals, Inc. 
Portola is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics in the areas of thrombosis,
other hematologic disorders and inflammation for patients who
currently have limited or no approved treatment options. Portola's
current development-stage portfolio consists of three compounds
discovered through its internal research efforts and one discovered
by Portola scientists during their time at a prior company. 
Portola's two lead programs address significant unmet medical needs
in the area of thrombosis, or blood clots. Portola's lead compound
Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase
3 development for extended duration prophylaxis, or preventive
treatment, of a form of thrombosis known as venous thromboembolism,
or VTE, in acute medically ill patients. Currently, there is no
anticoagulant approved for extended duration VTE prophylaxis in this
population. 
Portola's second lead development candidate, PRT4445, is a
recombinant protein designed to reverse the anticoagulant activity in
patients treated with a Factor Xa inhibitor who suffer an
uncontrolled bleeding episode or undergo emergency surgery. Portola
has entered into a collaboration agreement with Bristol-Myers Squibb
Company and Pfizer Inc. and a collaboration agreement with Bayer
Pharma AG and Janssen Pharmaceuticals, Inc. to study PRT4445 with
ELIQUIS(R) and XARELTO(R), respectively, in Portola's Phase 2 study.
Portola retains full, worldwide commercial rights with respect to
PRT4445. 
Portola's third product candidate, PRT2070, is an orally available
kinase inhibitor being developed for hematologic, or blood, cancers
and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase,
or Syk, and janus kinases, or JAK, enzymes that regulate important
signaling pathways. Subject to regulatory approval, Portola plans to
initiate a Phase 1/2 clinical study of PRT2070 in 2013 in patients
with B-cell hematologic cancers who have failed or relapsed on
existing marketed therapies or products in development, including
patients with identified mutations. Portola's fourth product
candidate, PRT2607, is a highly selective inhibitor of Syk and is
being developed by Portola's partner Biogen Idec Inc. for
inflammatory disorders. 
Joey Fleury
BrewLife
415.946.1090
jfleury@brewlife.com